Entries by Ines Sommer

Early detection of vulvar and vaginal cancer is overdue

There is still no targeted method for early detection of vulvar and vaginal cancer. This is despite the fact that an estimated 45,240 women worldwide were diagnosed with vulvar cancer in 2020, and more than 17,000 people even died from it. Vaginal cancer occurs slightly less frequently – with around 18,000 new cases and 8,000 […]

The IVDR (In-vitro Diagnostic Medical Device Regulation)

The new IVDR (In-vitro Diagnostic Medical Device Regulation) has been in force since 26 May. As a result, numerous companies have had to adapt their approval processes and internal procedures. The new regulations also present oncgnostics with new challenges. For example, the molecular biological cancer tests now fall into the second highest risk level. This […]

,

PCR test detects cervical precancerous lesions

Jena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability of modern cancer-screening methods is cervical cancer. One step in the direction of abolishing this form of cancer has been taken by the German life […]

WHO recommends one-dose HPV vaccination for girls

The World Health Organisation (WHO) recommends the one-dose HPV vaccination of girls and women up to 21 years of age instead of the current two-time vaccination. The WHO wants to increase the vaccination rate in the fight against cervical cancer. In principle, we welcome this plan, but we also have reservations regarding the new recommendation[1]. […]

oncgnostics at EUROGIN 2022

The EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress. The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas […]

Oncgnostics receives award: Germany’s most innovative companies

The business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion of innovation areas. For the third time, Capital, together with the market research institute Statista, determined Germany’s most innovative companies. For this purpose, they brought […]

A startup turns 10 – oncgnostics grows with its employees

10 years ago a small, very motivated team founded the oncgnostics GmbH to improve cervical cancer screening. Since then, oncgnostics GmbH has been growing and with it the number of its employees. On the occasion of the anniversary, it is time to share the experiences of the employees of the biotech company. 10 years of […]

HPV Vaccination: Help against various Types of Cancer

The World Health Organization (WHO) sees an increasing HPV vaccination worldwide as a great opportunity in the fight against various types of cancer. At the organization’s annual meeting, WHO director Tedros Adhanom Ghebreyesus declared that he wanted to use the HPV vaccine more widely. The aim is to act against the globally increasing cases of […]

The Uterus – A Complex Organ

Almost half of mankind owns this organ and every human life starts in it: the uterus. At the latest, with the first menstruation every woman becomes aware of her own uterus. But how exactly does the female reproductive organ look and what functions does it fulfil? The uterus is one of the female internal reproductive […]

On the World Mental Health Day

Abnormal results in Cervical Cancer Screening may trigger symptoms of post-traumatic stress disorder. Oncgnostics GmbH draws attention to this on the annual World Mental Health Day on 10 October and points out that conspicuous Pap test results and/or positive HPV tests have a negative effect on the psyche of the women concerned. The company, which […]